Addition of anti‐CD25 to thymoglobulin for induction therapy: delayed return of peripheral blood CD25‐positive population
Authors:
- 17 November 2010
- journal article
- Published by Wiley in Clinical Transplantation
- Vol. 25 (2) , E132-E135
Abstract
Sageshima J, Ciancio G, Gaynor JJ, Chen L, Guerra G, Kupin W, Roth D, Ruiz P, Burke GW. Addition of anti‐CD25 to thymoglobulin for induction therapy: delayed return of peripheral blood CD25‐positive population. Clin Transplant 2011: 25: E132–E135. © 2010 John Wiley & Sons A/S.Abstract: An anti‐CD25 monoclonal antibody was added to thymoglobulin for induction therapy in simultaneous pancreas/kidney (SPK) recipients. T‐cell subsets including CD3 and CD25 were assessed by flow cytometry analysis in the peripheral blood of SPK (n = 88), and for comparison kidney transplant (KT) recipients were assessed. KT recipients were treated with daclizumab (anti‐CD25) alone (five doses; 1 mg/kg) (n = 27) or thymoglobulin alone (4–7 doses; 1 mg/kg) (n = 23). SPK recipients received daclizumab (two doses; 1 mg/kg) in addition to thymoglobulin (five doses; 1 mg/kg). The return of peripheral blood CD25+ cells was delayed for 45 d post‐transplantation in the SPK recipients where anti‐CD25 was added to thymoglobulin, compared to those KT recipients with thymoglobulin alone. This strategy may result in reduced allogeneic (donor‐specific) T effector cells at the time of solid organ transplantation.Keywords
This publication has 19 references indexed in Scilit:
- Functional implications of T cell receptor diversityCurrent Opinion in Immunology, 2009
- The Early Course of Kidney Allograft Rejection: Defining the Time When Rejection BeginsAmerican Journal of Transplantation, 2009
- A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow‐upClinical Transplantation, 2007
- Mechanisms of action of antithymocyte globulin: T-cell depletion and beyondLeukemia, 2007
- Antithymocyte Globulins Suppress Dendritic Cell Function by Multiple MechanismsTransplantation, 2007
- B-cell Activity of Polyclonal Antithymocyte GlobulinsTransplantation, 2006
- A Randomized Trial of Three Renal Transplant Induction Antibodies: Early Comparison of Tacrolimus, Mycophenolate Mofetil, and Steroid Dosing, and Newer Immune-Monitoring1Transplantation, 2005
- PROSPECTIVE, RANDOMIZED TRIAL OF THE EFFECT OF ANTIBODY INDUCTION IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION: THREE-YEAR RESULTS1Transplantation, 2004
- A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients1Transplantation, 2003
- The Role of T-Cell Costimulatory Activation Pathways in Transplant RejectionNew England Journal of Medicine, 1998